Literature DB >> 26205791

Peptide Backbone Composition and Protease Susceptibility: Impact of Modification Type, Position, and Tandem Substitution.

Halina M Werner1, Chino C Cabalteja1, W Seth Horne2.   

Abstract

The clinical utility of peptides is limited by their rapid degradation by endogenous proteases. Modification of the peptide backbone can generate functional analogues with enhanced proteolytic stability. Existing principles for the design of such oligomers have focused primarily on effective structural mimicry. A more robust strategy would incorporate a rational approach for engineering maximal proteolytic stability with minimal unnatural residue content. We report here the systematic comparison of the proteolytic resistance imparted by four backbone modifications commonly employed in the design of protease-stable analogues of peptides with complex folding patterns. The degree of protection was quantified as a function of modification type, position, and tandem substitution in the context of a long, unstructured host sequence and a canonical serine protease. These results promise to inform ongoing work to develop biostable mimics of increasingly complex peptides and proteins.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  foldamers; peptides; peptidomimetics; proteases; protein-protein interactions

Mesh:

Substances:

Year:  2015        PMID: 26205791      PMCID: PMC4721950          DOI: 10.1002/cbic.201500312

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  46 in total

1.  Peptide and peptoid foldamers in medicinal chemistry.

Authors:  W Seth Horne
Journal:  Expert Opin Drug Discov       Date:  2011-11-02       Impact factor: 6.098

Review 2.  Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.

Authors:  Lei Diao; Bernd Meibohm
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

Review 3.  The medicinal chemistry of peptides.

Authors:  J J Nestor
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

Review 4.  Peptidomimetics via modifications of amino acids and peptide bonds.

Authors:  Ilker Avan; C Dennis Hall; Alan R Katritzky
Journal:  Chem Soc Rev       Date:  2014-03-13       Impact factor: 54.564

Review 5.  Small-molecule inhibitors of protein-protein interactions: progressing toward the reality.

Authors:  Michelle R Arkin; Yinyan Tang; James A Wells
Journal:  Chem Biol       Date:  2014-09-18

6.  A kinetic investigation of the crystallographically deduced binding subsites of bovine chymotrypsin A .

Authors:  D M Segal
Journal:  Biochemistry       Date:  1972-02-01       Impact factor: 3.162

Review 7.  Peptide drugs to target G protein-coupled receptors.

Authors:  Kathrin Bellmann-Sickert; Annette G Beck-Sickinger
Journal:  Trends Pharmacol Sci       Date:  2010-07-23       Impact factor: 14.819

8.  Cellular uptake of Aib-containing amphipathic helix peptide.

Authors:  Shun-ichi Wada; Hirokazu Tsuda; Terumi Okada; Hidehito Urata
Journal:  Bioorg Med Chem Lett       Date:  2011-08-11       Impact factor: 2.823

9.  Crystal and molecular structures of the complex of alpha-chymotrypsin with its inhibitor turkey ovomucoid third domain at 1.8 A resolution.

Authors:  M Fujinaga; A R Sielecki; R J Read; W Ardelt; M Laskowski; M N James
Journal:  J Mol Biol       Date:  1987-05-20       Impact factor: 5.469

10.  Beta-peptidic peptidomimetics.

Authors:  Dieter Seebach; James Gardiner
Journal:  Acc Chem Res       Date:  2008-06-26       Impact factor: 22.384

View more
  23 in total

1.  Heterogeneous-Backbone Foldamer Mimics of Zinc Finger Tertiary Structure.

Authors:  Kelly L George; W Seth Horne
Journal:  J Am Chem Soc       Date:  2017-06-05       Impact factor: 15.419

2.  Tuning of protease resistance in oligopeptides through N-alkylation.

Authors:  Revital Kaminker; Athina Anastasaki; Will R Gutekunst; Yingdong Luo; Sang-Ho Lee; Craig J Hawker
Journal:  Chem Commun (Camb)       Date:  2018-08-23       Impact factor: 6.222

3.  Backbone Modification of a Parathyroid Hormone Receptor-1 Antagonist/Inverse Agonist.

Authors:  Ross W Cheloha; Tomoyuki Watanabe; Thomas Dean; Samuel H Gellman; Thomas J Gardella
Journal:  ACS Chem Biol       Date:  2016-08-17       Impact factor: 5.100

4.  Foldamer Tertiary Structure through Sequence-Guided Protein Backbone Alteration.

Authors:  Kelly L George; W Seth Horne
Journal:  Acc Chem Res       Date:  2018-04-19       Impact factor: 22.384

5.  Comparison of design strategies for α-helix backbone modification in a protein tertiary fold.

Authors:  Nathan A Tavenor; Zachary E Reinert; George A Lengyel; Brian D Griffith; W Seth Horne
Journal:  Chem Commun (Camb)       Date:  2016-03-07       Impact factor: 6.222

6.  Recognition of Class II MHC Peptide Ligands That Contain β-Amino Acids.

Authors:  Ross W Cheloha; Andrew W Woodham; Djenet Bousbaine; Tong Wang; Shi Liu; John Sidney; Alessandro Sette; Samuel H Gellman; Hidde L Ploegh
Journal:  J Immunol       Date:  2019-08-07       Impact factor: 5.422

7.  Heterogeneous-Backbone Foldamer Mimics of a Computationally Designed, Disulfide-Rich Miniprotein.

Authors:  Chino C Cabalteja; Daniel S Mihalko; W Seth Horne
Journal:  Chembiochem       Date:  2018-11-27       Impact factor: 3.164

8.  Synthesis and biological evaluation of S-lipidated lipopeptides of a connexin 43 channel inhibitory peptide.

Authors:  Sung-Hyun Yang; Connor A Clemett; Margaret A Brimble; Simon J O'Carroll; Paul W R Harris
Journal:  RSC Med Chem       Date:  2020-07-10

9.  Development of Potent, Protease-Resistant Agonists of the Parathyroid Hormone Receptor with Broad β Residue Distribution.

Authors:  Ross W Cheloha; Bingming Chen; Niyanta N Kumar; Tomoyuki Watanabe; Robert G Thorne; Lingjun Li; Thomas J Gardella; Samuel H Gellman
Journal:  J Med Chem       Date:  2017-10-24       Impact factor: 7.446

Review 10.  Discovery of Antivirals Using Phage Display.

Authors:  Esen Sokullu; Marie-Soleil Gauthier; Benoit Coulombe
Journal:  Viruses       Date:  2021-06-10       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.